Page URL:

California stem cell institute ruled 'constitutional'

24 April 2006
By BioNews
Appeared in BioNews 355

A US court has ruled that the law that created the California Institute of Regenerative Medicine (CIRM) was in fact constitutional. The claimants in the lawsuit challenging the setting up of the CIRM were arguing that the institute, which is authorised to distribute $3 billion in research grants for stem cell research projects in California, including those using human embryos, is unconstitutional because the spending of taxpayer's money must be under state control.

In November 2004, 59 per cent of Californians voted in favour of Proposition 71, which established the CIRM and authorised it to issue bonds to fund $3 billion of grants for human embryonic stem cell (ES cell) research in the state. But since then, two lawsuits - taken by pro-life and 'politically conservative interest groups' - have delayed the institute's operations. The lawsuits alleged that because the board members of the CIRM are not elected officials, they have no authority to distribute public funds. The delay caused by the lawsuits meant that the agency could not start work, meaning the issuing of funds for ES cell research was severely delayed.

Last November, in a hearing at the Alameda County Superior Court, Judge Bonnie Lewman Sabraw ruled that the legal arguments relied upon by the stem cell programme's opponents did not stand up, which should have meant that the first grants could then have been issued. Judge Sabraw had been asked to throw out the lawsuits, which were deliberately designed to disrupt the work of the State's stem cell agency. She said the plaintiffs had failed to overcome a fundamental presumption that voter mandates - such as that given to Proposition 71 - must be honoured unless they were 'clearly, positively and unmistakably unconstitutional'. However, the lawsuits were not thrown out in their entirety and a further hearing was scheduled.

Earlier this month, while waiting for the outcome of the lawsuits, a state panel authorised the CIRM to borrow up to $200 million from large philanthropic organisations in the form of 'bond anticipation notes' so that it could begin to issue grants. Six private organisations and charitable foundations came forward to purchase $14 million worth of short term bond anticipation notes to fund the CIRM until the legal challenges were settled. Robert Klein, chair of the CIRM, said that he will continue to work to secure another $36 million of bonds.

Now, Judge Sabraw has held that the CIRM is in fact constitutional, opening the way for the state to begin issuing funds for ES cell research. She reiterated the requirement that the plaintiffs had to show that Proposition 71 was 'clearly, positively and unmistakably unconstitutional' and said they had still failed to do so, and therefore that bonds issued by the CIRM would be valid. In what has been described as a 'strongly worded judgment', she said that the plaintiffs 'did not present any evidence that the state is appropriating funds for any purpose or benefit other than a public purpose, the public purpose declared in Proposition 71 of fighting disease and promoting the general economy of the state'.

Dana Cody, director of the Life Legal Defence Fund, one of the groups challenging the CIRM, said 'we are disappointed but not surprised with the judges ruling', adding that the judge had 'failed to engage our arguments and case law'. The challenging groups have vowed to appeal the decision to the California Supreme Court, which will cause further delays.

Calif. judge backs $3 billion stem-cell effort
Reuters |  22 April 2006
Calif. stem cell agency still in limbo
Yahoo Daily News |  22 April 2006
Court backs stem cell funding plan
San Francisco Chronicle |  22 April 2006
Judge upholds stem cell initiative
Los Angeles Times |  22 April 2006
16 November 2009 - by Nisha Satkunarajah 
The California Institute for Regenerative Medicine (CIRM) has awarded fourteen teams a total of $230 million for the advancement of stem cell therapy. The CIRM was created as a measure by the Californian State to fund work on human embryonic stem (ES) cells.Californian voters approved the 10-year, $3 billion effort in 2004 largely to get around restrictions on ES cell research imposed by the administration of President George W Bush. This year, President Obama's administration relaxed thes...
17 September 2007 - by Dr Kirsty Horsey 
The California Institute of Regenerative Medicine (CIRM) has appointed Professor Alan Trounson as its new president, following a committee vote on Friday last week. Professor Trounson is a renowned Australian scientist and currently the director of Monash University's stem cell program in Melbourne. The CIRM is...
27 November 2006 - by Antony Starza-Allen 
California's stem cell institute is to be given a cash injection of $181 million to fund research through to the end of next year. The California Institute for Regenerative Medicine (CIRM) will be given a $150 million loan from the state and has raised the extra $31...
10 April 2006 - by BioNews 
Stem cell researchers in the US are publishing a decreasing proportion of work on human embryonic stem (ES) cells, according to a study undertaken by the Stanford University Centre for Biomedical Ethics. The authors of the study suggest that the decrease in proportion is likely to be due - at least...
3 April 2006 - by BioNews 
The House of Delegates of the US state of Maryland has approved a bill that could bring as much as $15 million of state funding per year for stem cell research, making it the fourth US state to authorise the spending of public money on such research. The money will...
27 February 2006 - by BioNews 
A US court was today due to begin hearing the opening statements in a pair of lawsuits seeking to have the state of California's stem cell programme overturned. The claimants want to invalidate the law that created the California Institute of Regenerative Medicine (CIRM), which is authorised to distribute $3...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.